Alpinvest Partners B.v. adds Agile Therapeutics Inc (AGRX) to its portfolio

Agile Therapeutics Inc (AGRX) : Alpinvest Partners B.v. added new position in Agile Therapeutics Inc during the most recent quarter end. The investment management firm now holds 27,693 shares of Agile Therapeutics Inc which is valued at $191,912 , the company said in a statement filed on Aug 10, 2016 with the SEC.Agile Therapeutics Inc makes up approximately 0.32% of Alpinvest Partners B.v.’s portfolio.

Other Hedge Funds, Including , Blackrock Institutional Trust Company N.a. boosted its stake in AGRX in the latest quarter, The investment management firm added 11,254 additional shares and now holds a total of 99,720 shares of Agile Therapeutics Inc which is valued at $691,060. Blair William Coil sold out all of its stake in AGRX during the most recent quarter. The investment firm sold 11,000 shares of AGRX which is valued $79,090. Eam Investors sold out all of its stake in AGRX during the most recent quarter. The investment firm sold 132,343 shares of AGRX which is valued $927,724.California State Teachers Retirement System reduced its stake in AGRX by selling 1,300 shares or 4.46% in the most recent quarter. The Hedge Fund company now holds 27,834 shares of AGRX which is valued at $196,230.Rice Hall James Associates reduced its stake in AGRX by selling 206 shares or 0.81% in the most recent quarter. The Hedge Fund company now holds 25,317 shares of AGRX which is valued at $176,966. Agile Therapeutics Inc makes up approx 0.01% of Rice Hall James Associates’s portfolio.

Agile Therapeutics Inc closed down -0.07 points or -0.99% at $7 with 18,414 shares getting traded on Friday. Post opening the session at $7.06, the shares hit an intraday low of $6.97 and an intraday high of $7.11 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

Agile Therapeutics Inc. is a women’s health specialty pharmaceutical company. The Company is engaged in the development and commercialization of prescription contraceptive products. The Company’s product candidates are designed to provide women with contraceptive options. The Company has developed a transdermal patch technology called Skinfusion. The Company’s lead product candidate Twirla also known as AG200-15 is a once-weekly prescription contraceptive patch in Phase III clinical development. Twirla is a combined hormonal contraceptive (CHC) patch that contains the active ingredients ethinyl estradiol (EE) which is a synthetic estrogen and levonorgestrel (LNG) which is a type of progestin a synthetic steroid hormone. Twirla is designed using the Company’s Skinfusion technology to consistently deliver both hormones over a seven-day period at levels. The Company is also developing transdermal contraceptive products including AG200-ER AG200-SP and AG890.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *